


- Sensibilità paragonabile a quella di SPECT e PET
- Consente imaging molecolare (in vitro, ex-vivo)
- Applicazioni in chirurgia guidata ed endoscopia
- Possibilità di agenti switchable (responsive)
- Possibilità di *time-resolved detection* (autofluorescenza di fondo)
- No quantificazione


- Window
- Stokes shift
- Brightness
- Stability




# Esempio di *switchable fluorescent probe* sensore di <sup>1</sup>O<sub>2</sub>

(a) Singlet Oxygen Probes


Key reaction: Endoperoxide formation




Reaction scheme for detection of singlet oxygen




## **FRET** *fluorescence* – *resonance energy transfer*



II FRET è attivo solo quando i due cromofori distano fra loro pochi nanometri (<10 nm) e hanno la giusta orientazione reciproca.




# quantum dots (QD) nano-cristalli di semiconduttori (e.g. CdSe)




Ampio intervallo di frequenze di eccitazione, banda di emissione stretta, molto intensa e modulabile con le dimensioni del QD


# Complessi dei lantanidi



## Upconverting QDs e LnNPs




# Dark-field fluorescence imaging con AuNP




EGFR = *epidermal growth factor receptor*, marcatore tumorale

# Complessi polipiridilici di Ru(II) come DNA light switch





# G-quadruplex sensing





# Sviluppi futuri

# Multimodal imaging agents and theranostics









Si stima che nel 2050 a livello mondiale le morti da infezione batterica – dovute soltanto a ceppi di batteri resistenti – arriveranno a 50 milioni all'anno nella sola comunità Europea (1/3 di tutte le morti).

#### Corriere della Sera, maggio 2024

#### L'antibiotico-resistenza causa quasi 5 milioni di morti ogni anno: l'allame degli esperti su Lancet

di Cristina Marrone

Le infezioni batteriche sono la seconda causa di morte nel mondo: sempre più spesso funghi e batteri non rispondono ai farmaci. Neonati e anziani i più colpiti




Ο

Cerca il tuo organo/patologia

#### The Lancet, maggio 2024

#### Antimicrobial resistance: an enormous, growing, and unevenly distributed threat to global health

Each year, an estimated 7.7 million deaths are associated with bacterial infections



4.95m are associated with antimicrobial resistance (AMR)

1·27m

of which are caused by bacterial pathogens resistant to the antibiotics available to treat them **Rising AMR has been documented over the past two decades.** Projections from

high-income countries predict resistance to third-line antibiotics the last-resort drugs—could be 2.1 times higher in 2035 compared to 2005 2-1 times higher

2005

2035

# nature

<u>Explore content</u>  $\checkmark$  About the journal  $\checkmark$  Publish with us  $\checkmark$ 

nature > articles > article


Article Published: 26 March 2025

# A broad-spectrum lasso peptide antibiotic targeting the bacterial ribosome

*la Repubblica* 27 marzo 2025 L'ultimo "nuovo" antibiotico tre decenni fa


La resistenza antimicrobica, AMR, è una delle più grandi sfide per la salute pubblica mondiale, con milioni di persone che ogni anno muoiono a causa di infezioni resistenti agli antibiotici. L'ultima volta che una nuova classe di antibiotici è stata introdotta sul mercato risale a quasi tre decenni fa.

#### Timeline: a brief history of the use of Silver




Metallo massivo – Nanoparticelle – Sali (Ag+)

# Multiple mechanism of action of Ag<sup>+</sup> ions



# WHY CHOOSE SILVER PLATING FOR MEDICAL DEVICES?

## Silver salts



# silver sulfadiazine





# Silver nanoparticles (AgNPs)




Estimated 2014 production of commercial AgNPs: 320 t







# Ag<sup>+</sup> release from AgNPs




## Uptake of AgNPs




# Multiple mechanism of action of Ag<sup>+</sup> ions




## Multiple mechanism of action of AgNP's




#### Antibacterial Ag-NHC compounds







Drug candidate: high activity against tobramycin-resistant pathogenic bacteria *in vitro* as well as *in vivo*. Improved stability to hydrolysis due to the electron-withdrawing CI substituents that pull electron density from the carbene


# Other strategies: metal modification of known antibiotics




#### **Platensimycin mimics**








# Other metals: As, Sb, Bi, Hg



Antimicrobial agent introduced in early 1900 for the treatment of the deadly bacterial infection *Syphilis*. Later replaced by modern antibiotics


#### Antiparasitic compounds



melarsoprol


treatment of sleeping sickness (African trypanosomiasis)

#### Anti-leishmaniasis compounds



Sb, reduced to Sb(III), inhibits *trypanothione reductase*, an essential enzyme of the parasite


## Infezioni da Helicobacter pylori






#### bismuth subsalicylate

#### The pink stuff (introduced 1901)




CBS



#### bismuto subcitrato colloidale


## Infezioni da Helicobacter pylori



ranitidine bismuth citrate



### Antibacterial mercury compounds



# Fosrenol<sup>TM</sup>: $La_2(CO_3)_3 \cdot 4H_2O$ a success story



FOSRENOL Chewable Tablets FOSRENOL Oral Powder Phosphorus Burden in ESRD Conferences and Resources

Patient

Support

To reduce serum phosphate in patients with end-stage renal disease (ESRD)


#### HELP IT FALL WITH FOSRENOL\* (lanthanum carbonate)

\*Phosphorus reductions maintained for up to 3 years in patients remaining on therapy (n=46)<sup>1-3</sup>

- FOSRENOL Chewable Tablets: Approved in 2004 and used in US clinical practices for more than a decade<sup>4,5</sup> LEARN MORE
- FOSRENOL Oral Powder: Available since May 2015, offering you another approved administration option<sup>6</sup> LEARN MORE

Approved by FDA in 2004 for the treatment of hyperphosphatemia (increased phosphate levels in serum) in patients with end stage renal disease.

Phosphate metabolism is intimately linked with calcium metabolism, and is regulated by parathyroid hormone (PTH) and vitamin D



Pathological consequences of hyperphosphatemia: cardiac and vascular tissue calcification, bone malformations in the joints

The ideal phosphate binder should:

- have a high affinity for phosphate
- be able to bind dietary phosphate rapidly in the guts
- have low solubility
- little or no systemic absorption
- be non-toxic
- be available as a palatable oral dosage form, with a low pill burden

Calcium phosphate binders (e.g. calcium carbonate or calcium acetate) are effective....however, calcium can be absorbed, resulting in hypercalcemia and increased risk of cardiovascular calcification.

# Fosrenol<sup>™</sup>: a success story

Among the many lanthanide salts screened,  $La_2(CO_3)_3 \cdot 4H_2O$  possessed the best phosphate binding properties:

- Optimal binding at pH 3–5, but retains binding activity in the full pH range of 1–7
- It is very insoluble and the La<sup>3+</sup> cation does not cross biological membranes (when given by the oral route, >90% excreted in the feces, and <0.001% absorbed)</li>
- No toxicity observed in animal studies, in particular no direct effects on calcium, vitamin D, or PTH metabolism

Fosrenol<sup>TM</sup> represents a significant improvement in treatment options for patients with end-stage renal disease.

- in the acidic environment of the stomach lanthanum carbonate dissociates sufficiently to allow formation of a highly insoluble phosphate.
- It has the required pharmacokinetic properties, it is poorly absorbed, with both the parent salt and the phosphate product being eliminated in the feces.
- Because of the lack of absorption it has no systemic toxicity, it has no detrimental effect on calcium, vitamin D or PTH metabolism, and is safe and well tolerated.
- Its effectiveness as a phosphate binder results in a lower pill burden for patients, an advantage over competing medications.